Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Assets Average (2024 - 2025)

NewAmsterdam Pharma's Assets Average history spans 2 years, with the latest figure at $777.9 million for Q4 2025.

  • For Q4 2025, Assets Average rose 19.32% year-over-year to $777.9 million; the TTM value through Dec 2025 reached $777.9 million, up 19.32%, while the annual FY2025 figure was $817.0 million, 34.84% up from the prior year.
  • Assets Average for Q4 2025 was $777.9 million at NewAmsterdam Pharma, down from $800.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $841.5 million in Q1 2025 and bottomed at $417.8 million in Q1 2024.